The Parkinson Disease and Movement Disorders Center at Boston University Medical Campus has a long established clinical research program. Research is ongoing and includes observational and interventional research in pharmacology and rehabilitation.
Clinical research staff includes four board-certified neurologists with specialty training in movement disorders, three nurse specialists, two research assistants, and one regulatory manager. Staff are members of the Parkinson Study Group and Huntington’s Study Group. The Center is designated an American Parkinson Disease Association Center for Advanced Research.
Imaging specific to Parkinson’s disease and other movement disorders including MRI, CT, and SPECT, are available at Boston University Medical Center. Boston Medical Center is certified in DaTScan. The facility supports the collection of laboratory samples including routine labs, pharmacokinetics, and DNA collection and storage.
Collaborative and Complementary Research at Boston University
For additional information, contact Marie-Hélène Saint Hilaire, MD, FRCP(C), at email@example.com.
APDA Center for Advanced Research
Boston University School of Medicine is home to an Advanced Center for Parkinson’s Research supported by the American Parkinson Disease Association. The Center is directed by Marie Hélène Saint-Hilaire, MD, FRCPC, with a comprehensive team of experts.
APDA Centers for Advanced Research must meet the highest academic standards and be distinguished leaders in the field of PD research. There are eight such centers across the country.
The funding of this Center supports a large research program, which includes: Biomarker studies, studies of non-motor symptoms, studies of self-management strategies, an active clinical trials program, 3500 patient visits per year, a Deep Brain Stimulation program, and a fellowship program in Movement Disorders.
The American Parkinson Disease Association (APDA) is the largest grassroots network dedicated to fighting Parkinson’s disease (PD) and works tirelessly to assist the more than 1 million Americans with PD live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $170 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease. To join us in the fight against Parkinson’s disease and to learn more about the support APDA provides nationally through our network of Chapters and Information & Referral (I&R) Centers, as well as our national Research Program and Centers for Advanced Research, please visit us at www.apdaparkinson.org.
Parkinson’s disease affects more than 1 million people in the United States annually, with at least 60,000 new cases diagnosed each year. The chronic and progressive neurological condition is the second most common neurodegenerative aging disorder, after Alzheimer’s disease.
For more information contact:
Medical Director: Marie-Hélène Saint Hilaire, MD, FRCP(C)
Ongoing Clinical Trials
There are several ongoing research opportunities. For information, please contact Ray James, RN at (617) 638-7745 or Cathi Thomas, MS, RN at (617) 638-7737. Listed below are trials currently recruiting subjects. Institutional Review Board approval has been obtained to publicize these trials.
- Parkinson’s Progression Markers Initiative Study (PPMI)
- Early Stage Parkinson’s Research Study (PRISM)
- Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease
- Early Longitudinal Imaging in a Parkinson’s Progression Markers Initiative (PPMI)
- Telehealth Treatment for Depression in Parkinson’s Disease
- FireUp PD Research Survey
- Evaluation of a New Medication for Early Parkinson’s (Pharma2B)
- Study on Medication for Early Parkinson’s (SPARK)
- Walking Health is Paramount in Parkinson Disease (WHIP-PD)
- Biomarker Study (SEARCH PD)